Poly(ADP-ribose) polymerase inhibitors in combination with androgen-receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations. Here, we describe the design and rationale of the multinational, phase III, TALAPRO-3 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with mCSPC and HRR gene alterations. The primary end point is investigator-assessed radiographic progression-free survival (rPFS) per RECIST 1.1 in soft tissue, or per PCWG3 criteria in bone. The TALAPRO-3 study will demonstrate whether the addition of talazoparib can improve the efficacy of enzalutamide as assessed by rPFS in patients with mCSPC and HRR gene alterations undergoing androgen deprivation therapy. NCT04821622 (ClinicalTrials.gov) Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC. 29 March 2021.

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2023-0526DOI Listing

Publication Analysis

Top Keywords

talazoparib enzalutamide
12
hrr gene
12
gene alterations
12
phase iii
8
study talazoparib
8
metastatic castration-sensitive
8
castration-sensitive prostate
8
prostate cancer
8
talapro-3 study
8
patients mcspc
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!